SAGA awarded €450,000 grant from Sweden’s SWElife Innovation Program

SAGA awarded €450,000 grant from Sweden’s SWElife Innovation Program

LUND, Sweden — /November 15, 2018/ — SAGA Diagnostics announced today it has been awarded a follow-on grant of SEK 4.7 million (~ €450,000) from the SWElife Accelerator Innovation Program to support the product development objectives of SAGA’s ultrasensitive technologies for monitoring cancer patients using simple blood samples and other “liquid biopsies”. The grant will […]

WntResearch selects SAGA’s ctDNA monitoring tool KROMA for phase 2 clinical trial

WntResearch selects SAGA’s ctDNA monitoring tool KROMA for phase 2 clinical trial

LUND, Sweden — /August 30, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with WntResearch AB, a Swedish biopharma company advancing new anti-cancer therapies targeting the Wnt5A pathway.  WntResearch is […]

SAGA inks deal with Center for Molecular Diagnostics for lung cancer and leukemia tests

SAGA inks deal with Center for Molecular Diagnostics for lung cancer and leukemia tests

LUND, Sweden — /June 14, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with the Center for Molecular Diagnostics, Region Skåne, part of the Skåne University Hospital system serving the […]

IBSAFE results in acute myeloid leukemia presented at Keystone Symposium Stockholm

IBSAFE results in acute myeloid leukemia presented at Keystone Symposium Stockholm

STOCKHOLM, Sweden — /May 8, 2018/ — Interim data on minimal residual disease (MRD) detection in acute myeloid leukemia (AML) patients was presented today by Dr. Louise Pettersson, MD (Pathology, Halmstad Hospital), at the Keystone Symposium on Precision Medicine in Cancer, Stockholm, Sweden.  Dr. Pettersson’s study was an abstract selected for oral presentation by the international […]

Strong Winds Fill Sails of Successful Seed Round for SAGA Diagnostics

Strong Winds Fill Sails of Successful Seed Round for SAGA Diagnostics

LUND, Sweden — /March 15, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has raised €1.0 million EUR seed capital from international investors (10.5 million SEK = $1.25 million USD). Participants in the round include serial […]

Make a difference – join SAGA Diagnostics as Business Development Manager

Make a difference – join SAGA Diagnostics as Business Development Manager

Seeking a growth-oriented business development leader to join us in our mission to revolutionize cancer diagnostics and monitoring through proprietary ultrasensitive technologies to measure a new class of biomarker, circulating tumor DNA. Your role will include identifying, evaluating and executing transformative partnerships, collaborations, and deals across pharmaceutical and academic clinical trials, biotechnology, and healthcare industries. […]

European Commission H2020 SME Instrument Phase 1 Grant Awarded!

European Commission H2020 SME Instrument Phase 1 Grant Awarded!

We are pleased to announce that SAGA Diagnostics has been awarded the Phase 1 grant (€50,000) from the EU European Commission Horizon 2020 Program SME Instrument!  In this highly competitive commersialization program, our application was evaluated with top marks in all categories.  “Being awarded this grant is a strong signal that we are on the […]

SAGA Wins a SKAPA Innovation Award!

SAGA Wins a SKAPA Innovation Award!

SAGA Diagnostics’ CEO Lao Saal (pictured 3rd from left) and CTO Anthony George were awarded the prestigious SKAPA Foundation Innovation Award in the Memory of Alfred Nobel for their development of ultrasensitive technologies to measure circulating tumor DNA.  Lao and Anthony are among two regional winners for Skåne in south Sweden in the Innovation category […]

SAGA wins 1st Place in NLSDays 2017 StartUp Pitch Competition!

SAGA wins 1st Place in NLSDays 2017 StartUp Pitch Competition!

Out of 16 Nordic companies, SAGA Diagnostics won 1st place for best pitch in the Nordic Life Science Days 2017 StartUp Pitch Competition, a Bionordic event sponsored by Johnson & Johnson Innovation, SmiLe Incubator and Medeon Science Park & Incubator. The award includes mentoring from Johnson & Johnson Innovation and complimentary registration including a 6-minute company presentation […]

CEO Lao Saal interviewed by BBC World News

CEO Lao Saal interviewed by BBC World News

SAGA Diagnostics CEO, Lao Saal, recognized expert on cancer genomics and precision medicine, was invited for a live TV interview by the BBC World News on July 4th 2017.  View the 3-minute clip here https://www.linkedin.com/feed/update/urn:li:activity:6288117550924599297/.

Biotech Leader Bio-Rad to Evaluate SAGA Diagnostics’ Technology

Biotech Leader Bio-Rad to Evaluate SAGA Diagnostics’ Technology

LUND, Sweden — /June 14, 2017/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive monitoring of circulating tumor DNA in cancer patients, today announces an agreement with a global provider of life science and clinical diagnostic products, Bio‑Rad Laboratories, Inc. (NYSE: BIO and BIOb), who will evaluate one of […]